CYC3

CYC3 is a small molecule inhibitor specifically targeting Aurora Kinase A, developed by Cyclacel. It has demonstrated preclinical activity in pancreatic cancer models, where it induces M-phase cell cycle arrest and apoptosis. Research indicates that CYC3 synergizes with low concentrations of paclitaxel, potentially offering a therapeutic strategy that maintains efficacy while reducing myelotoxicity associated with high-dose taxane treatment. Mathematical modeling and in vitro assays in MiaPaCa-2 and Panc-1 cells suggest that the combination of CYC3 and low-dose paclitaxel achieves similar growth inhibition to high-dose paclitaxel with a significantly improved safety profile in colony-forming unit assays.